[ad_1]
AstraZeneca earned $ 275 million in revenue from the non-profit Covid-19 vaccine in the first quarter, while sales of anti-cancer drugs and growth in new markets helped the physician exceed earnings and sales expectations.
The pharmaceutical company has confirmed its full-year revenue forecast for a small percentage of teens, with basic earnings per share rising faster, ranging from $ 4.75 to $ 5.
Pascal Soriot, CEO of AstraZeneca, said it has performed well despite the pandemic delaying the diagnosis and treatment of many conditions.
“We made strong progress in the first quarter of 2021 and continued to advance our portfolio of life-changing medicines,” he said. “We expect Covid’s impact to reduce and predict performance acceleration in the second half of 2021.”
AstraZeneca has revenue of $ 7.3 billion, excluding the contribution of the vaccine it has developed in conjunction with Oxford University, up 15 per cent year-on-year and higher than projected at $ 7 billion.
Oncology sales were up 20% on the same period last year, and revenue from new markets rose 14%, while in China it was up 19%.
Basic earnings per share rose 55 percent to $ 1.63, beating the analyst’s average of $ 1.48.
[ad_2]
Source link
